Please ensure Javascript is enabled for purposes of website accessibility

Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today

By Dan Caplinger – Updated Apr 10, 2018 at 4:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out what helped send the market higher.

Stocks continued their roller-coaster ride on Tuesday as major benchmarks scored impressive gains. Even though investors seemed to lose momentum toward the end of the session on Monday, positive comments from Chinese officials succeeded in easing fears about a potential trade war, and that helped refocus most market participants on the impending start to earnings season. Good news for certain individual stocks also helped power the indexes higher. Sprint (S), Spectrum Pharmaceuticals (SPPI -4.85%), and NVIDIA (NVDA 0.32%) were among the best performers on the day. Here's why they did so well.

Sprint looks for a deal

Shares of Sprint climbed 17% in the wake of news that the telecom company might once again be in talks to get an acquisition bid from rival wireless carrier T-Mobile US (TMUS -0.92%). The on-again, off-again deal has been in the works for years without having made progress, but the realities of needing to address the huge costs of upgrading to new 5G network standards poses a substantial competitive obstacle that could make a combination more rewarding. Antitrust concerns will remain intact, especially given that a Sprint/T-Mobile merger would reduce the number of major carriers in the U.S. market to just three. Nevertheless, hope springs eternal, and investors seem to have at least some confidence that a deal might get done.

Laptop with a Sprint label on it in front of a background of green bushes.

Image source: Sprint.

Spectrum releases promising results

Spectrum Pharmaceuticals stock soared 42% after the company released an update from a promising clinical trial. The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression-free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease. Conducted at the MD Anderson Cancer Center, the study shows "additional insight into just how meaningful poziotinib may be in this area of high unmet need," according to CEO Joe Turgeon. There's still a long way to go before clinical studies are complete, but the news is still promising for shareholders in the biotech.

NVIDIA gets favorable comments

Finally, shares of NVIDIA jumped 6%. The graphics chip giant gained ground following comments about the company from stock analysts at Needham & Company, who said that concerns among some investors are unfounded. Some have feared that falling prices for bitcoin and other cryptocurrencies could hurt demand for NVIDIA products, and that self-driving car accidents could slow down artificial intelligence efforts. Yet NVIDIA still has plenty of demand from actual gamers who provide the core demand for graphics processing chips, and shareholders seem to be more confident now that NVIDIA can bounce back from its recent slump to become stronger than ever. Meanwhile, Morgan Stanley also pointed to NVIDIA's dominance in GPUs as a compelling factor for the stock.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Nvidia. The Motley Fool recommends T-Mobile US. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sprint Stock Quote
Sprint
S
Spectrum Pharmaceuticals Stock Quote
Spectrum Pharmaceuticals
SPPI
$0.43 (-4.85%) $0.02
Nvidia Stock Quote
Nvidia
NVDA
$132.09 (0.32%) $0.42
T-Mobile US Stock Quote
T-Mobile US
TMUS
$141.23 (-0.92%) $-1.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.